NGNE

$19.05-0.14 (-0.73%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$19.05
Potential Upside
5%
Whystock Fair Value$20.00
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$295.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-32.06%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
18.39

Recent News

MarketBeat
Mar 21, 2026

Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference

Neurogene (NASDAQ:NGNE) CEO and founder Rachel McMinn outlined the company’s progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lea

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Fly
Feb 27, 2026

Block upgraded, Duolingo downgraded: Wall Street's top analyst calls

Block upgraded, Duolingo downgraded: Wall Street's top analyst calls

BEARISH
Negative press. News cycle fixated on risk factors or misses.
24/7 Wall St.
Feb 27, 2026

Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More

Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts’ earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the ... Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Feb 14, 2026

Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit

Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail said at Guggenheim’s 2026 Emerging Outlook Biotech Summit. Mikail described Rett syndrome as a “de

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Nov 26, 2025

Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.